Abstract
In September, 2021, WHO published the 22nd edition of its Model List of Essential Medicines, including insulin analogues and SGLT2 inhibitors.1 Insulin has been on WHO's Model List of Essential Medicines since it was first published in 1977. Although the 21st list, which was published in 2019, included only soluble and intermediate-acting insulin and the oral hypoglycaemic agents gliclazide, glibenclamide, and metformin as medicines for people with diabetes, the new edition added insulin degludec, insulin detemir, and insulin glargine, including quality-assured biosimilars.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
